ViewRay, Inc. designs, manufactures, and markets the MRIdian MRI-guided Radiation Therapy System. The company is headquartered in Oakwood Village, Ohio and currently employs 295 full-time employees. The company went IPO on 2014-11-04.
Leveraging in-depth analyst evaluations, we have synthesized key insights from expert assessments to present a positive outlook for VRAYQ. Analysts highlight solid fundamentals and favorable market sentiment, suggesting upside potential in the near term. Based on this thorough expert analysis, we maintain an optimistic view of this stock. Our conclusion: VRAYQ is a Buy candidate.
VRAYQ stock price ended at $0 on 金曜日, after rising NaN%
On the latest trading day Mar 20, 2026, the stock price of VRAYQ rose by NaN%, climbing from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. Notably, trading volume dropped by 99 shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 300 shares were traded, equating to a market value of approximately --.